104 related articles for article (PubMed ID: 28011817)
1. A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
Sutoh Yoneyama M; Tobisawa Y; Hatakeyama S; Sato M; Tone K; Tatara Y; Kakizaki I; Funyu T; Fukuda M; Hoshi S; Ohyama C; Tsuboi S
J Biochem; 2017 Jun; 161(6):479-492. PubMed ID: 28011817
[TBL] [Abstract][Full Text] [Related]
2. Implications of altered O-glycosylation in tumour immune evasion.
Itano N
J Biochem; 2019 May; 165(5):387-390. PubMed ID: 30649348
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans.
Tsuboi S; Sutoh M; Hatakeyama S; Hiraoka N; Habuchi T; Horikawa Y; Hashimoto Y; Yoneyama T; Mori K; Koie T; Nakamura T; Saitoh H; Yamaya K; Funyu T; Fukuda M; Ohyama C
EMBO J; 2011 Jun; 30(15):3173-85. PubMed ID: 21712812
[TBL] [Abstract][Full Text] [Related]
4. MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.
Suzuki Y; Sutoh M; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Habuchi T; Arai Y; Fukuda M; Ohyama C; Tsuboi S
Int J Oncol; 2012 Jun; 40(6):1831-8. PubMed ID: 22446589
[TBL] [Abstract][Full Text] [Related]
5. Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.
Okamoto T; Yoneyama MS; Hatakeyama S; Mori K; Yamamoto H; Koie T; Saitoh H; Yamaya K; Funyu T; Fukuda M; Ohyama C; Tsuboi S
Mol Med Rep; 2013 Feb; 7(2):359-64. PubMed ID: 23165940
[TBL] [Abstract][Full Text] [Related]
6. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Gil-Julio H; Perea F; Rodriguez-Nicolas A; Cozar JM; González-Ramirez AR; Concha A; Garrido F; Aptsiauri N; Ruiz-Cabello F
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298868
[TBL] [Abstract][Full Text] [Related]
7. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
[TBL] [Abstract][Full Text] [Related]
8. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
9. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
Mangino G; Grazia Capri M; Barnaba V; Alberti S
Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
[TBL] [Abstract][Full Text] [Related]
10. TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells.
Chen XH; Liu ZC; Zhang G; Wei W; Wang XX; Wang H; Ke HP; Zhang F; Wang HS; Cai SH; Du J
Mol Immunol; 2015 May; 65(1):34-42. PubMed ID: 25618241
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
[TBL] [Abstract][Full Text] [Related]
12. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?
Chang CC; Campoli M; Ferrone S
Curr Opin Immunol; 2004 Oct; 16(5):644-50. PubMed ID: 15342012
[TBL] [Abstract][Full Text] [Related]
13. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
14. Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression.
Baba T; Hanagiri T; Takenoyama M; Shiota H; Kuroda K; Shigematsu Y; Ichiki Y; Uramoto H; So T; Yasumoto K
Cancer Sci; 2010 Oct; 101(10):2115-20. PubMed ID: 20649604
[TBL] [Abstract][Full Text] [Related]
15. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
16. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance.
Wang YH; Cao YW; Yang XC; Niu HT; Sun LJ; Wang XS; Liu J
Asian Pac J Cancer Prev; 2014; 15(3):1321-6. PubMed ID: 24606459
[TBL] [Abstract][Full Text] [Related]
17. Core 2 β1,6-N-acetylglucosaminyltransferases accelerate the escape of choriocarcinoma from natural killer cell immunity.
Nakamura K; Niimi K; Yamamoto E; Ikeda Y; Nishino K; Suzuki S; Kajiyama H; Kikkawa F
Biochem Biophys Rep; 2021 Jul; 26():100951. PubMed ID: 33644424
[TBL] [Abstract][Full Text] [Related]
18. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer.
Ferris RL; Whiteside TL; Ferrone S
Clin Cancer Res; 2006 Jul; 12(13):3890-5. PubMed ID: 16818683
[TBL] [Abstract][Full Text] [Related]
19. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
[TBL] [Abstract][Full Text] [Related]
20. Evidence for cytotoxic T lymphocyte response against human lung cancer: reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I.
Calhoun RF; Naziruddin B; Enriquez-Rincon F; Duffy BF; Ritter JM; Sundaresan S; Patterson GA; Cooper JD; Mohanakumar T
Surgery; 2000 Jul; 128(1):76-85. PubMed ID: 10876189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
